A New Brand of Surgery: Dr. David Samadi

In 2017, Mitt Romney, the prominent politician, underwent one of the newest forms of prostate surgery. In March 2017, Romney was diagnosed with a large tumor on his prostate, something that many men of all ages fear. With prostate cancer, there are generally only two forms of treatment. If the tumor has not spread, the prostate can be operated on. However, this usually leaves several urological functions either damaged or completely destroyed. Another option is radiology, which tends to have a much lower success rate and is awful for the patient. However, thanks to doctors like Dr. David Samadi, there is now another option, which Mitt Romney wholeheartedly accepted. This final option is robotic surgery.

Mitt Romney is completely free of his cancer now, according to Dr. Samadi, but what is this new procedure? With the risks associated with any form of operation around that area of the body, getting free of cancer has the possibility of greatly changing a person’s life with the old form of surgery. With robotic surgery, much of the human error and judgment is taken out of the equation, and robots perform most of the tasks associated with the surgery. This leads to much lower blood loss, smaller incisions, and higher precision. All of this leads to a less invasive and more successful surgery.

Dr. David Samadi has been working on these surgeries for years. In fact, he has performed over 7,000 of these surgeries since he started, and he is known as the world leader in robotic urological surgery. Dr. Samadi’s general philosophy is that cancer patients are already inconvenienced enough by their illness, so they should not have to be subject to the old ways of getting rid of that illness too.

Dr. Samadi attended the State University of New York’s Stony Brook School of Medicine, where he graduated with his Master’s in 1994. The then attended Montefiore Medical Center, where he earned his MD in Urology. Samadi has had several trainings and fellowships at such places as the Henri Mondor Hospital in France, the Memorial Sloan-Kettering Cancer Center, and the Albert Einstein College of Medicine.

Dr. David Samadi is now the Chairmen of Urology and the Chief of Robotic Surgery at Lenox Hill Hospital. He previously held the post as the Chief of Robotics Division in the Department of Urology at Mount Saini Hospital in New York. Dr. Samadi has translated his knowledge into several published articles and even has his own international lecture circuit.

Eric Lefkofsky: Creating an Innovation in Medicine

Humanity have reached a point where in fatal diseases and pandemics are being eradicated one by one. The joint efforts between physicians and scientists have resulted to the creation of cure for several diseases, and it managed to prolong the life expectancy of humanity. Eric Lefkofsky, a business man, entrepreneur, and a scientist, wanted to invest in the partnership between scientists and physicians so that he can create a computerized weapon that will target pathogens. He would like to create a vast network that will hold thousands and even millions of information from scientists and physicians around the world. He would like to catalog every single pathogen, along with the disease that they carry, and the effects of these diseases to humans. Through the system that he is developing, Eric Lefkofsky is positive that global scientists and physicians would accept the invention that he conceptualized and at least put up some effort to give the project a go signal.

According to Eric Lefkofsky, once he finished the network, scientists and physicians could be more open to each other. He believes that through communication, the world becomes a smaller place, and people tend to meet up with old friends whom they have never seen for long. Eric Lefkofsky added that the reason why he wanted to work with physicians and scientists is that he loves researching and finding out something. Aside from his ventures within the scientific community, Eric Lefkofsky is still busy with his project entitled Tempus. Tempus is an advanced form of technology that is being used to store sensitive and commercial information about a disease. Once the physicians have taken a sample from their patients, these samples are being taken to the system. The system then categorizes all of the information stored with in them. This is very helpful especially for scientists and physicians who are living outside the confines of their comfort zone.

Eric Lefkofsky stated that he is very thankful with the creation of Tempus. He thanked those who have put up their trust on him, and once again, Eric Lefkofsky stated that he will be upgrading the system soon, so that more people can use it without thinking that the machine is difficult.


Clay Siegall And Seattle Genetics’s Grand Plans Of Creating More Drugs

The cancer research community based in Puget Sound region is on the spotlight. That is due to the recent visit of Joe Biden, Vice President of the United States. Seattle Genetics, a cancer drug company is part of what is making the region special with its rapid expansion. Located in Bothell, Seattle Genetics is trying to increase its drugs while widening the use of its initial drug. Additionally, it is on a hiring spree. The move shows the company’s ambitiousness. It also underscores Seattle’s major role as a leading cancer research region.


Seattle Genetics is trying out Adcetris, its only commercialized drug in several cancer treatment scenarios. According to CEO Clay Siegall, presently, the tests are being carried out in over 70 trials against several types of lymphomas. Particularly, the firm is carrying out a phase 3. It is an advanced clinical trial of Adcetris as a leading treatment for Hodgkin lymphoma that has been newly diagnosed or previously untreated. Siegall noted that the trials have had a major impact on the company.


Last year, Adcetris racked up $226 million in sales in the United States and Canada. In 2016, the sales projection for the drug that is mainly used to fight lymphomas is between $255 and $275 in the two countries. Adcetris is sold outside the United States and Canada by Takeda Pharmaceutical, the company’s partner.


Siegall noted that Adcetris is just one drug among the firm’s many. Seattle Genetics has 12 drugs that it is currently developing. This year, the firm wants to get an additional drug into Phase 3 clinical trials. The drug is called 33A. It will be used in treating acute myeloid leukemia. Additionally, Seattle Genetics has a drug for breast cancer as well as two drugs for bladder cancer. Siegall pointed out that in 2016, they will disseminate considerable information on the three drugs.


In the meantime, the firm is on a hiring spree. This year, it plans to add 100 professionals in the United States and nearly 20 for its Switzerland office. So far, the company has over 800 employees.


About Clay Siegall

Clay Siegall is the president and CEO of Seattle Genetics. He co-founded the cancer drug company in 1998. Siegall also serves as the company’s board chairman. He is a trained scientist that majored on targeted cancer therapies. Siegall established the firm on a strong foundation of rigorous research, scientific innovation, and drug development practices. He has led the company to become a leader in the development of antibody-drug conjugates for cancer treatment.

Original Sources: